Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 26 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pembrolizumab with chemotherapy for treating advanced or recurrent endometrial cancer	Chemotherapy , Pembrolizumab (Keytruda; MK-3475)	Endometrial cancer	Female Reproductive Cancer	2023	View \| Download
Pembrolizumab with Lenvatinib and chemotherapy for previously untreated advanced or metastatic gastroesophageal adenocarcinoma	Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Gastroesophageal adenocarcinoma	Gastrointestinal Cancer	2023	View \| Download
Pembrolizumab with radiotherapy and chemotherapy for treating unresectable oesophageal cancer	Chemotherapy , Pembrolizumab (Keytruda; MK-3475) , Radiotherapy	Oesophageal cancer	Head and Neck Cancer	2023	View \| Download
Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line	Chemotherapy , Polatuzumab vedotin (DCDS4501A; RG7596; RG-7596; Polivy)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2020	View \| Download
Tislelizumab with chemotherapy for previously untreated unresectable or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma	Chemotherapy , Tislelizumab (BGB-A317; BGBA-317)	Gastric cancer , Gastro-oesophageal junction adenocarcinoma	Gastrointestinal Cancer	2022	View \| Download
Toripalimab with chemotherapy for previously untreated recurrent or metastatic nasopharyngeal carcinoma	Chemotherapy , Toripalimab	Nasopharyngeal carcinoma	Head and Neck Cancer	2023	View \| Download